Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55,705,828
-
Total 13F shares
-
13,365,697
-
Share change
-
+152,428
-
Total reported value
-
$19,647,483
-
Price per share
-
$1.47
-
Number of holders
-
46
-
Value change
-
+$254,060
-
Number of buys
-
13
-
Number of sells
-
17
Institutional Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q4 2023
As of 31 Dec 2023,
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,365,697 shares.
The largest 10 holders included
Anson Funds Management LP, VANGUARD GROUP INC, ADAR1 Capital Management, LLC, Atlas Venture Life Science Advisors, LLC, Alphabet Inc., Murchinson Ltd., RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, and AMERIPRISE FINANCIAL INC.
This page lists
46
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.